1. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Issue 3 (March 2021) Authors: Zhou, Caicun; Chen, Gongyan; Huang, Yunchao; Zhou, Jianying; Lin, LiZhu; Feng, Jifeng; Wang, Zhehai; Shu, Yongqian; Shi, Jianhua; Hu, Yi; Wang, QiMing; Cheng, Ying; Wu, Fengying; Chen, Jianhua; Lin, Xiaoyan; Wang, Yongsheng; Huang, Jianan; Cui, Jiuwei; Cao, Lejie; Liu, Yunpeng Journal: Lancet Issue: Volume 9:Issue 3(2021) Page Start: 305 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CMAB009 plus irinotecan versus irinotecan‐only as second‐line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild‐type metastatic colorectal cancer patients: promising findings from a prospective, open‐label, randomized, phase III trial. Issue 1 (24th May 2019) Authors: Shi, Yuankai; Li, Jin; Xu, Jianming; Sun, Yan; Wang, Liwei; Cheng, Ying; Liu, Wei; Sun, Guoping; Chen, Yigui; Bai, Li; Zhang, Yiping; He, Xiaohui; Luo, Yi; Wang, Zhehai; Liu, Yunpeng; Yao, Qiang; Li, Yuhong; Qin, Shukui; Hu, Xiaohua; Bi, Feng Journal: Cancer communications Issue: Volume 39:Issue 1(2019) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review. Issue 10 (24th August 2020) Authors: Shan, Qinge; Wang, Haiyong; Han, Xiao; Guo, Jun; Wang, Zhehai Journal: Thoracic cancer Issue: Volume 11:Issue 10(2020) Page Start: 3001 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial. (16th February 2020) Authors: Cheng, Ying; Han, Baohui; Li, Kai; Wang, Qiming; Zhang, Li; Shi, Jianhua; Wang, Zhehai; He, Jianxing; Shi, Yuankai; Chen, Weiqiang; Wang, Xiuwen; Luo, Yi; Nan, Kejun; Jin, Faguang; Li, Baolan; Zhu, Jing Journal: Cancer medicine Issue: Volume 9:Number 8(2020) Page Start: 2621 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study. (September 2017) Authors: Han, Baohui; Li, Kai; Wang, Qiming; Zhao, Yizhuo; Zhang, Li; Shi, Jianhua; Wang, Zhehai; Cheng, Yin; He, Jianxing; Shi, Yuankai; Chen, Weiqiang; Wang, Xiuwen; Luo, Yi; Nan, Kejun; Jin, Faguang; Li, Baolan; Chen, Yinlan; Zhou, Jianying; Wang, Donglin Journal: Lancet oncology Issue: Volume 18(2017)Supplement 1 Page Start: S3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study. (September 2022) Authors: Zhang, Li; Wang, Zhehai; Fang, Jian; Yu, Qitao; Han, Baohui; Cang, Shundong; Chen, Gongyan; Mei, Xiaodong; Yang, Zhixiong; Stefaniak, Victoria; Lin, Yong; Wang, Shuyan; Zhang, Wen; Sun, Luyao; Yang, Yunpeng Journal: Lung cancer Issue: Volume 171(2022) Page Start: 56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303. Issue 3 (21st January 2019) Authors: Si, Xiaoyan; Zhang, Li; Wang, Hanping; Zhang, Xiaotong; Wang, Mengzhao; Han, Baohui; Li, Kai; Wang, Qiming; Shi, Jianhua; Wang, Zhehai; Cheng, Ying; Shi, Yuankai; Chen, Weiqiang; Wang, Xiuwen; Luo, Yi; Nan, Kejun; Jin, Faguang Journal: Thoracic cancer Issue: Volume 10:Issue 3(2019) Page Start: 551 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Molecular subtyping of small‐cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies. Issue 2 (28th October 2022) Authors: Wang, Haiyong; Wu, Shuangxiu; Li, Zhenzhen; Zhang, Chenyue; Shang, Xiaoling; Zhao, Chenglong; Li, Zhenxiang; Lin, Jiamao; Guo, Jun; Wang, Zhehai Journal: Cancer science Issue: Volume 114:Issue 2(2023) Page Start: 665 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy. Issue 12 (4th November 2022) Authors: Wu, Fengying; Jiang, Tao; Chen, Gongyan; Huang, Yunchao; Zhou, Jianying; Lin, Lizhu; Feng, Jifeng; Wang, Zhehai; Shu, Yongqian; Shi, Jianhua; Hu, Yi; Wang, Qiming; Cheng, Ying; Chen, Jianhua; Lin, Xiaoyan; Wang, Yongsheng; Huang, Jianan; Cui, Jiuwei; Cao, Lejie; Liu, Yunpeng Journal: Cancer communications Issue: Volume 42:Issue 12(2022) Page Start: 1331 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Occurrence of hypertension during third‐line anlotinib is associated with progression‐free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial. Issue 17 (17th July 2021) Authors: Shi, Jianhua; Chen, Guimin; Wang, Haitao; Wang, Xiuxiu; Han, Baohui; Li, Kai; Wang, Qiming; Zhang, Li; Wang, Zhehai; Cheng, Ying; He, Jianxing; Shi, Yuankai; Chen, Weiqiang; Luo, Yi; Wu, Lin; Wang, Xiuwen; Nan, Kejun; Jin, Faguang; Dong, Jian; Li, Baolan Journal: Thoracic cancer Issue: Volume 12:Issue 17(2021) Page Start: 2345 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗